openPR Logo
Press release

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Pipeline Review, H2 2017

11-03-2017 01:54 PM CET | Health & Medicine

Press release from: MarketResearchReports.biz

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or

"The Report Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Neprilysin-Pipeline Review, H2, outlays comprehensive information on the Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

View Report @ https://www.marketresearchreports.biz/reports/1361335/neprilysin-neutral-endopeptidase-2411-or-atriopeptidase-or-common-acute-lymphocytic-leukemia-antigen-or-skin-fibroblast-elastase-or-enkephalinase-or-cd10-or-mme-or-ec-342411-pipeline-review-h2-2017-market-research-reports

Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Neprilysin also known as membrane metallo-endopeptidase (MME) is an enzyme that is encoded by the MME gene. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P and bradykinin. It degrades the amyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been a cause of Alzheimers disease. Inhibition of neprilysin helps in treatment of Pain and hypertension. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Metabolic Disorders and Gastrointestinal which include indications Chronic Heart Failure, Acute Heart Failure, Cancer Pain, Diabetic Nephropathy, Hypertension, Pain, Acute Pain, Alzheimers Disease, Diabetic Neuropathic Pain, Migraine, Neuropathic Pain, Ocular Pain, Post-Myocardial Infarction and Resistant Hypertension.

Furthermore, this report also reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/1361335

Scope

- The report provides a snapshot of the global therapeutic landscape for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
- The report reviews Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Overview
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Companies Involved in Therapeutics Development
Bioprojet SCR
Novartis AG
Pharmaleads SA
Theravance Biopharma Inc
Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Drug Profiles
(sacubitril + valsartan)-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexecadotril-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LHW-090-Drug Profile

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neprilysin (Neutral Endopeptidase 24.11 or Atriopeptidase or Common Acute Lymphocytic Leukemia Antigen or Skin Fibroblast Elastase or Enkephalinase or CD10 or MME or EC 3.4.24.11)-Pipeline Review, H2 2017 here

News-ID: 801010 • Views:

More Releases from MarketResearchReports.biz

Hydro-flyers Market: Moving Towards a Brighter Future
Hydro-flyers Market: Moving Towards a Brighter Future
A hydro-flyer is an adventure sporting device which uses the propulsion of water jet technology to create continuous flight movement, where the lift and movement are controlled by the flyer. Hydro-flyers sporting devices make use of the flow of water power to drive the flyer to reach soaring heights. The rise in water sporting facilities is one of the major factors that promote the growth and demand for hydro-flyers in
Outdoor Floodlights: Technology and Market Dynamics
Outdoor Floodlights: Technology and Market Dynamics
Outdoor floodlights is a reliable, highly efficient, and economical solution for a wide range of outdoor applications. These lights are resistant to temperature fluctuations and they remain stable even in extreme climatic conditions. Unlike the traditional lights, floodlights remain stable and functional even in harsh climatic conditions. This makes them ideal for use in any climate and any outdoor application. Outdoor floodlights save a significant amount of energy and consume
Snow Helmets Market Future Prospects and Regional Outlook
Snow Helmets Market Future Prospects and Regional Outlook
Riders are riding faster and getting bolder day by day. Hence, safety equipment need to be updated as per the requirement and changing time. Earlier, helmets were primarily used by extreme skiers and racers. They were used only on slopes. However, later, the use of helmets was made compulsory. Earlier, bulky black helmets were used by riders, which are outdated at present. Currently, new stylish helmets that can match with
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Predictions for 2019: Global Sparkling Water Dispensers Industry Is Set to Boom
Sparkling water dispensers are equipment used for dispensing carbonated water. These dispensers mix the still, filtered water with carbon dioxide before dispensing. Sparkling water dispensers are mostly used in households and commercial establishments such as amusement parks, hotels, restaurants, and sports arenas. A sparkling water dispenser has separate outlets for hot water and cold water. The hot water outlet does not require a separate filtration process. However, cold water is

All 5 Releases


More Releases for Neprilysin

Anti-Neprilysin Market Growth in Future Scope 2025-2032 | BIOPROJET, Novartis AG …
Latest Report, titled "Anti-Neprilysin Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The Anti-Neprilysin market has been expanding significantly in recent
Neprilysin Market to see Rapid Growth by 2031
Neprilysin Market was valued at USD Billion in 2023 and is expected to grow at a CAGR of 23% between 2024 and 2031. Neprilysin Market research report is one of the effective ways to target customers and satisfy their growing needs as it gathers all the significant market data. It allows tracking future business growth for the forthcoming duration 2024-2031. It further helps to categorize objectives for the business while
Neprilysin Market Demand Makes Room for New Growth Story | Bioprojet SCR, Novart …
The Latest published market study on Neprilysin Market, Global Outlook and Forecast Market provides an overview of the current market dynamics in the Neprilysin Market, Outlook and Forecast space, as well as what our survey respondents- all outsourcing decision-makers- predict the market will look like in 2029. The study breaks the market by revenue and volume (wherever applicable) and price history to estimate the size and trend analysis and identify
Global Anti-Neprilysin Market Size,Share and Growth,2022-2028|
Report Overview Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Anti-Neprilysin estimated at in the year 2022, is projected to reach a revised size of by 2028, growing at a CAGR of during the forecast period 2022-2028. The USA market for Anti-Neprilysin is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of
Neprilysin Market Share 2021 Growth Challenges, Opportunities and Future Trends …
The global neprilysin market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Neprilysin is a zinc-dependent metalloprotease. It cleaves peptides at the amino side of hydrophobic residues as well as inactivates several peptide hormones such as glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. The major factor driving the growth of the market is the rising prevalence of hypertension across the globe. According to the
Anti-Neprilysin Market Latest Technological Advancements, Scope, Applications an …
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry